• 1
    Iosif S, Batra S, Ek A, Astedt B. Oestrogens receptors in the human female lower urinary tract. Am J Obstet Gynaecol 1981;141: 817820.
  • 2
    Batra SC, Iosif LS. Progesterone receptors in the female urinary tract. J Urol 1987;138: 130134.
  • 3
    Iosif C, Bekassy Z. Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynaecol Scand 1984;63: 257260.
  • 4
    CardozoLD, TappA, VersiE, SamsioeG, Bonne EricksonP, editors. The lower urinary tract in peri- and postmenopausal women. In: The Urogenital Deficiency Syndrome. Bagsverd, Denmark: Novo Industri AS.1987: 1017.
  • 5
    Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA sequence, expression and homology to v-erbA. Nature 1986;320: 134139.
  • 6
    Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel oestrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93: 59255930.
  • 7
    Warner M, Nilsson S, Gustafsson JA. The oestrogen receptor family. Curr Opin Obstet Gynaecol 1999;11: 249254.
  • 8
    Rud T, Anderson KE, Asmussen M, et al. Factors maintaining the urethral pressure in women. Invest Urol 1980;17: 343347.
  • 9
    Kinn AC, Lindskog M. Oestrogens and phenylpropanolamine in combination for stress incontinence. Urology 1988;32: 273280.
  • 10
    Matsubara S, Okada H, Shirakawa Gotoh A, Kuno T, Kamidono S. Oestrogen levels influence beta-3-adrenceptor-mediated relaxation of the female rat detrusor muscle. Urology 2002;59: 621625.
  • 11
    Smith PJB. The effect of oestrogens on bladder function in the female. In: CampbellS, editor. The Management of the Menopause and Postmenopausal Years. Carnforth: MTP, 1976: 291298.
  • 12
    Samsioe G, Jansson I, Mellstrom D, Svandborg A. Occurance, nature and treatment of urinary incontinence in a 70 year old female population. Maturitas 1985;7: 335342.
  • 13
    Hextall A, Bidmead J, Cardozo L, Hooper R. Hormonal influences on the human female lower urinary tract: a prospective evaluation of the effects of the menstrual cycle on symptomatology and the results of urodynamic investigation. Neurourol Urodyn 1999;18: 282283.
  • 14
    Van Geelen JM, Doesburg WH, Thomas CMG. Urodynamic studies in the normal menstrual cycle: the relationship between hormonal changes during the menstrual cycle and the urethral pressure profile. Am J Obstet Gynaecol 1981;141: 384392.
  • 15
    Benness C, Gangar K, Cardozo LD, Cutner A. Do progestogens exacerbate urinary incontinence in women on HRT? Neurourol Urodyn 1991;10: 316318.
  • 16
    Elliot RA, Castleden CM. Effect of progestagens and oestrogens on the contractile response of rat detrusor muscle to electrical field stimulation. Clin Sci 1994;87: 342.
  • 17
    Fantl JA, Cardozo LD, McClish DK, and the Hormones and Urogenital Therapy Committee. Oestrogen therapy in the management of incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynaecol 1994;83: 1218.
  • 18
    Zullo MA, Oliva C, Falconi G, Paparella P, Mancuso S. Efficacy of oestrogen therapy in urinary incontinence. A meta-analytic study. Minerva Ginecol 1998;50: 199205.
  • 19
    Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Synder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynaecol 2001;97: 116120.
  • 20
    Moeher B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women [Cochrane review]. In: The Cochrane Library, Issue 3. Oxford: Update Software, 2003.
  • 21
    Caine M, Raz S. The role of female hormones in stress incontinence. In: Proceedings of the 16th Congress of the International Society of Urology. Amsterdam, the Netherlands.
  • 22
    Rud T. The effects of oestrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women. Acta Obstet Gynaecol Scand 1980;59: 265270.
  • 23
    Wilson PD, Faragher B, Butler B, Bullock D, Robinson EL, Brown ADG. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol 1987;94: 568574.
  • 24
    Walter S, Wolf H, Barlebo H, Jansen H. Urinary incontinence in postmenopausal women treated with oestrogens: a double-blind clinical trial. J Urol 1978;33: 135143.
  • 25
    Fantl JA, Bump RC, Robinson D, et al. Efficacy of oestrogen supplementation in the treatment of urinary incontinence. Obstet Gynaecol 1996;88: 745749.
  • 26
    Jackson S, Shepherd A, Brookes S, Abrams P. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo controlled trial. Br J Obstet Gynaecol 1999;106: 711718.
  • 27
    Sultana CJ, Walters MD. Oestrogen and urinary incontinence in women. Maturitas 1995;20: 129138.
  • 28
    Ahmed Al-Badr Ross S, Soroka D, Drutz HP. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence? J Obstet Gynaecol Can 2003;25: 567574.
  • 29
    Samsicoe G, Jansson I, Mellstrom D, Svanberg A. Urinary incontinence in 75 year old women. Effects of oestriol. Acta Obstet Gynaecol Scand 1985;93: 57.
  • 30
    Cardozo LD, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas 1993;18: 4753.
  • 31
    Nilsson K, Heimer G. Low dose oestradiol in the treatment of urogenital oestrogen defiiciency—a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15: 121127.
  • 32
    Benness C, Wise BG, Cutner A, Cardozo LD. Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women. Int Urogynaecol J 1992;3: 281.
  • 33
    Eriksen PS, Rasmussen H. Low dose 17β-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol 1992;44: 137144.
  • 34
    Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. Br J Obstet Gynaecol 2000;107: 10291034.
  • 35
    Cardozo L, Lose G, McClish D, Versi E. Estrogen treatment for symptoms of an overactive bladder, results of a meta analysis. Int J Urogynaecol 2001;12: V.
  • 36
    Brandberg A, Mellstrom D, Samsioe G. Low dose oral oestriol treatment in elderly women with urogenital infections. Acta Obstet Gynaecol Scand 1987;140: 3338.
  • 37
    Parsons CL, Schmidt JD. Control of recurrent urinary tract infections in postmenopausal women. J Urol 1982;128: 12241226.
  • 38
    Privette M, Cade R, Peterson J, et al. Prevention of recurrent urinary tract infections in postmenopausal women. Nephron 1988; 50: 2427.
  • 39
    Kjaergaard B, Walter S, Knudsen A, et al. Treatment with low dose vaginal oestradiol in postmenopausal women. A double blind controlled trial. Ugeskr Laeger 1990;152: 658659.
  • 40
    Raz R, Stamm WE. A controlled trial of intravaginal oestriol in postmenopausal women with recurrent urinary tract infections. New Eng J Med 1993;329: 753756.
  • 41
    Kirkengen AL, Anderson P, Gjersoe E, et al. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scan J Prim Health Care 1992;10: 142.
  • 42
    Cardozo LD, Benness C, Abbott D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. Br J Obstet Gynaecol 1998;105: 403407.
  • 43
    Eriksen B. A randomised, open, parallel-group study on the preventitive effect of an oestradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynaecol 1999;180: 10721079.